8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 10, 2026·SEC
Material company update
Jan 12, 2026·SEC
Exelixis, Inc.(EXEL)Earnings, Financials & Key Ratios
EXEL•NASDAQ
18.7× P/E·Price updated Jun 19, 2026
AboutExelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.Show more
- Revenue$2.32B+7.0%
- EBITDA$901M+42.3%
- Net Income$783M+50.1%
- EPS (Diluted)2.78+58.0%
- Gross Margin96.39%
- EBITDA Margin38.84%+33.0%
- Operating Margin37.59%+34.8%
- Net Margin33.73%+40.3%
- ROE35.53%+53.6%
EXEL Key Insights
Exelixis, Inc. (EXEL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 22.5%
- ✓Strong 5Y profit CAGR of 47.6%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 36.4% free cash flow margin
- ✓Momentum leader: RS Rating 81 (top 19%)
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EXEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EXEL Price & Volume
Exelixis, Inc. (EXEL) stock price & volume — 10-year historical chart
Loading chart...
EXEL Growth Metrics
Exelixis, Inc. (EXEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years51.19%
5 Years18.63%
3 Years12.93%
TTM3.33%
Profit CAGR
10 Years-
5 Years47.58%
3 Years62.53%
TTM29.5%
EPS CAGR
10 Years-
5 Years51.35%
3 Years70.59%
TTM37.9%
Return on Capital
10 Years19.33%
5 Years17.37%
3 Years21.74%
Last Year35.01%
EXEL Recent Earnings
Exelixis, Inc. (EXEL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.87+13.7%
$0.77
Rev
$611M+0.5%
$608M
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$0.94+22.1%
$0.77
Rev
$599M+0.4%
$597M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.78+13.9%
$0.69
Rev
$598M+1.3%
$590M
Q3 2025
Jul 28, 2025Metric
Actual
Est
EPS
$0.75+15.4%
$0.65
Rev
$568M-4.5%
$595M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.87vs $0.77+13.7% | $611Mvs $608M+0.5% |
| Q1 2026 | Feb 10, 2026 | $0.94vs $0.77+22.1% | $599Mvs $597M+0.4% |
| Q4 2025 | Nov 4, 2025 | $0.78vs $0.69+13.9% | $598Mvs $590M+1.3% |
| Q3 2025 | Jul 28, 2025 | $0.75vs $0.65+15.4% | $568Mvs $595M-4.5% |
Based on last 12 quarters of dataView full earnings history →
EXEL Peer Comparison
Exelixis, Inc. (EXEL) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INCY | 19.62B | 98.22 | 15.32 | 21.22% | 26.71% | 29.31% | 0.01 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 |
Compare EXEL vs Peers
Exelixis, Inc. (EXEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EXEL Income Statement
Exelixis, Inc. (EXEL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Jan'25 | Jan'26 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 452.48M | 853.83M | 967.77M | 987.54M | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B | 2.38B |
Revenue Growth % | 136.34% | 88.7% | 13.35% | 2.04% | 45.31% | 12.27% | 13.6% | 18.49% | 6.98% | 3.33% |
Cost of Goods Sold | 15.07M | 26.35M | 33.1M | 36.27M | 52.87M | 57.91M | 72.55M | 76.22M | 83.7M | 64.53M |
COGS % of Revenue | 3.33% | 3.09% | 3.42% | 3.67% | 3.68% | 3.59% | 3.96% | 3.51% | 3.61% | - |
Gross Profit | 437.41M▲ 0% | 827.48M▲ 89.2% | 934.68M▲ 13.0% | 951.27M▲ 1.8% | 1.38B▲ 45.3% | 1.55B▲ 12.4% | 1.76B▲ 13.2% | 2.09B▲ 19.0% | 2.24B▲ 6.9% | 1.7B▲ 0% |
Gross Margin % | 96.67% | 96.91% | 96.58% | 96.33% | 96.32% | 96.41% | 96.04% | 96.49% | 96.39% | 71.57% |
Gross Profit Growth % | 136.56% | 89.18% | 12.96% | 1.77% | 45.29% | 12.38% | 13.17% | 19.05% | 6.88% | - |
Operating Expenses | 271.53M | 388.62M | 565.21M | 841.21M | 1.1B | 1.35B | 1.59B | 1.49B | 1.36B | 1.37B |
OpEx % of Revenue | 60.01% | 45.52% | 58.4% | 85.18% | 76.34% | 83.9% | 86.7% | 68.61% | 58.8% | - |
Selling, General & Admin | 159.33M | 206.37M | 228.24M | 293.36M | 401.71M | 459.86M | 542.71M | 492.13M | 518.73M | 521.15M |
SG&A % of Revenue | 35.21% | 24.17% | 23.58% | 29.71% | 27.99% | 28.54% | 29.65% | 22.69% | 22.36% | - |
Research & Development | 112.17M | 182.26M | 336.96M | 547.85M | 693.72M | 891.81M | 1.04B | 910.41M | 825M | 599.44M |
R&D % of Revenue | 24.79% | 21.35% | 34.82% | 55.48% | 48.34% | 55.36% | 57.05% | 41.98% | 35.56% | - |
Other Operating Expenses | 0 | 397K | 680K | 912K | -184K | -197K | 0 | 85.33M | 20.51M | 3M |
Operating Income | 165.91M▲ 0% | 438.86M▲ 164.5% | 369.47M▼ 15.8% | 110.06M▼ 70.2% | 286.67M▲ 160.5% | 201.48M▼ 29.7% | 170.88M▼ 15.2% | 604.62M▲ 253.8% | 872.19M▲ 44.3% | 936.67M▲ 0% |
Operating Margin % | 36.67% | 51.4% | 38.18% | 11.14% | 19.98% | 12.51% | 9.34% | 27.88% | 37.59% | 39.43% |
Operating Income Growth % | 689.92% | 164.51% | -15.81% | -70.21% | 160.46% | -29.71% | -15.19% | 253.82% | 44.26% | - |
EBITDA | 167.1M | 443.77M | 380.64M | 119.2M | 300.3M | 222.36M | 196.6M | 633.42M | 901.25M | 958.38M |
EBITDA Margin % | 36.93% | 51.97% | 39.33% | 12.07% | 20.93% | 13.8% | 10.74% | 29.21% | 38.84% | 40.34% |
EBITDA Growth % | 716.09% | 165.58% | -14.23% | -68.68% | 151.92% | -25.95% | -11.58% | 222.18% | 42.28% | 21.04% |
D&A (Non-Cash Add-back) | 1.19M | 4.92M | 11.17M | 9.14M | 13.63M | 20.88M | 25.72M | 28.8M | 29.05M | 21.71M |
EBIT | 167.11M | 438.86M | 398.11M | 110.06M | 286.67M | 201.48M | 170.88M | 689.95M | 892.7M | 718.74M |
Net Interest Income | -3.8M | 12.84M | 27.96M | 19.86M | 7.67M | 33.06M | 86.54M | 77.16M | 69.21M | 50.14M |
Interest Income | 4.88M | 12.84M | 27.96M | 19.86M | 7.67M | 33.06M | 86.54M | 77.16M | 69.21M | 66.26M |
Interest Expense | 8.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -7.33M | 13.24M | 28.64M | 20.78M | 7.49M | 32.87M | 86.64M | 77.02M | 69.02M | 50.18M |
Pretax Income | 158.58M▲ 0% | 452.09M▲ 185.1% | 398.11M▼ 11.9% | 130.84M▼ 67.1% | 294.15M▲ 124.8% | 234.35M▼ 20.3% | 257.52M▲ 9.9% | 681.64M▲ 164.7% | 941.21M▲ 38.1% | 1B▲ 0% |
Pretax Margin % | 35.05% | 52.95% | 41.14% | 13.25% | 20.5% | 14.55% | 14.07% | 31.43% | 40.57% | 42.23% |
Income Tax | 4.35M | -237.98M | 77.1M | 19.06M | 63.09M | 52.07M | 49.76M | 160.37M | 158.64M | 169.78M |
Effective Tax Rate % | 2.74% | -52.64% | 19.37% | 14.56% | 21.45% | 22.22% | 19.32% | 23.53% | 16.85% | 16.92% |
Net Income | 154.23M▲ 0% | 690.07M▲ 347.4% | 321.01M▼ 53.5% | 111.78M▼ 65.2% | 231.06M▲ 106.7% | 182.28M▼ 21.1% | 207.76M▲ 14.0% | 521.27M▲ 150.9% | 782.57M▲ 50.1% | 833.42M▲ 0% |
Net Margin % | 34.09% | 80.82% | 33.17% | 11.32% | 16.1% | 11.31% | 11.35% | 24.04% | 33.73% | 35.08% |
Net Income Growth % | 319.63% | 347.44% | -53.48% | -65.18% | 106.71% | -21.11% | 13.98% | 150.89% | 50.13% | 29.5% |
Net Income (Continuing) | 154.23M | 690.07M | 321.01M | 111.78M | 231.06M | 182.28M | 207.76M | 521.27M | 782.57M | 833.42M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.49▲ 0% | 2.21▲ 351.0% | 1.02▼ 53.8% | 0.35▼ 65.7% | 0.72▲ 105.7% | 0.56▼ 22.2% | 0.65▲ 16.1% | 1.76▲ 170.8% | 2.78▲ 58.0% | 3.12▲ 0% |
EPS Growth % | 275% | 351.02% | -53.85% | -65.69% | 105.71% | -22.22% | 16.07% | 170.77% | 57.95% | 37.9% |
EPS (Basic) | 0.52 | 2.32 | 1.06 | 0.36 | 0.73 | 0.57 | 0.65 | 1.80 | 2.88 | - |
Diluted Shares Outstanding | 312M | 312.8M | 315.01M | 318M | 322.36M | 324.56M | 321.46M | 296.13M | 281.86M | 267.32M |
Basic Shares Outstanding | 293.59M | 297.89M | 302.58M | 308.27M | 314.88M | 321.53M | 318.15M | 290.03M | 271.57M | 258.33M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EXEL Balance Sheet
Exelixis, Inc. (EXEL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Jan'25 | Jan'26 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 484.87M | 897.02M | 1.01B | 1.45B | 1.83B | 1.62B | 1.32B | 1.47B | 1.44B | 1.21B |
Cash & Short-Term Investments | 387.77M | 693.33M | 852.24M | 1.21B | 1.47B | 1.31B | 995.3M | 1.11B | 1.06B | 777.21M |
Cash Only | 183.16M | 314.77M | 266.5M | 319.22M | 647.17M | 501.19M | 262.99M | 217.37M | 482.49M | 226.15M |
Short-Term Investments | 204.61M | 378.56M | 585.74M | 887.32M | 819.9M | 807.27M | 732.31M | 893.9M | 576.6M | 551.05M |
Accounts Receivable | 81.19M | 162.77M | 119.07M | 160.88M | 282.65M | 214.78M | 237.41M | 265.44M | 286.92M | 328.95M |
Days Sales Outstanding | 65.5 | 69.58 | 44.91 | 59.46 | 71.9 | 48.66 | 47.35 | 44.67 | 45.14 | 46.78 |
Inventory | 6.66M | 9.84M | 12.89M | 20.97M | 27.49M | 33.3M | 17.32M | 22.39M | 21.69M | 26.61M |
Days Inventory Outstanding | 161.28 | 136.29 | 142.11 | 211.05 | 189.79 | 209.88 | 87.16 | 107.22 | 94.57 | 140.25 |
Other Current Assets | 504K | 0 | 0 | 0 | 0 | 62.21M | 67.93M | 68.48M | 75.6M | 75.88M |
Total Non-Current Assets | 170.42M | 525.27M | 874.48M | 691.94M | 781.49M | 1.45B | 1.62B | 1.48B | 1.4B | 1.38B |
Property, Plant & Equipment | 25.74M | 56.76M | 90.73M | 67.38M | 104.03M | 345.44M | 470.85M | 359.11M | 441.26M | 378.4M |
Fixed Asset Turnover | 17.58x | 15.04x | 10.67x | 14.66x | 13.79x | 4.66x | 3.89x | 6.04x | 5.26x | 6.71x |
Goodwill | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 64.25M | 157.19M | 536.38M | 332.31M | 371.11M | 756.73M | 728.72M | 637.29M | 603.6M | 1.78B |
Other Non-Current Assets | 16.74M | 3.52M | 11.31M | 71.85M | 131M | 55.77M | 0 | 0 | 0 | 649.14M |
Total Assets | 655.29M▲ 0% | 1.42B▲ 117.0% | 1.89B▲ 32.6% | 2.14B▲ 13.3% | 2.62B▲ 22.4% | 3.07B▲ 17.4% | 2.94B▼ 4.2% | 2.95B▲ 0.2% | 2.84B▼ 3.5% | 2.59B▲ 0% |
Asset Turnover | 0.69x | 0.60x | 0.51x | 0.46x | 0.55x | 0.52x | 0.62x | 0.74x | 0.82x | 0.87x |
Asset Growth % | 9.67% | 117.05% | 32.58% | 13.35% | 22.41% | 17.4% | -4.2% | 0.18% | -3.5% | -20.14% |
Total Current Liabilities | 115.17M | 105.47M | 142.75M | 204.66M | 337.59M | 324.36M | 394.28M | 403.77M | 405.64M | 370.98M |
Accounts Payable | 9.57M | 10.9M | 11.58M | 23.63M | 24.26M | 32.67M | 33.77M | 38.19M | 29.62M | 24.15M |
Days Payables Outstanding | 231.97 | 151.01 | 127.72 | 237.81 | 167.46 | 205.9 | 169.89 | 182.9 | 129.19 | 148.41 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 31.98M | 15.9M | 6.6M | 1.79M | 7.81M | 7.49M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 52.54M | 3.19M | 15.13M | 42.66M | 45.55M | 71.44M | 82.12M | 267.22M | 287.5M | 346.82M |
Current Ratio | 4.21x | 8.50x | 7.08x | 7.06x | 5.43x | 4.99x | 3.34x | 3.63x | 3.56x | 3.26x |
Quick Ratio | 4.15x | 8.41x | 6.99x | 6.96x | 5.35x | 4.89x | 3.30x | 3.58x | 3.50x | 3.19x |
Cash Conversion Cycle | -5.2 | 54.86 | 59.3 | 32.7 | 94.23 | 52.64 | -35.39 | -31.01 | 10.52 | 38.63 |
Total Non-Current Liabilities | 255.16M | 29.36M | 56.95M | 53.56M | 68.03M | 258.7M | 284.17M | 299.72M | 277.46M | 286.87M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 169.54M |
Capital Lease Obligations | 14.53M | 12.18M | 48.01M | 49.09M | 51.27M | 190.17M | 189.94M | 190.82M | 173.04M | 529.34M |
Deferred Tax Liabilities | -14.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 16.64M | 1.29M | 2.35M | 721K | 8.02M | 61.95M | 94.22M | 108.89M | 104.42M | 117.33M |
Total Liabilities | 370.33M | 134.83M | 199.7M | 258.22M | 405.62M | 583.06M | 678.45M | 703.49M | 683.1M | 657.85M |
Total Debt | 14.53M | 14.92M | 50.74M | 49.09M | 51.27M | 190.17M | 189.94M | 190.82M | 173.04M | 169.54M |
Net Debt | -168.63M | -299.86M | -215.76M | -270.13M | -595.9M | -311.02M | -73.05M | -26.55M | -309.45M | -56.61M |
Debt / Equity | 0.05x | 0.01x | 0.03x | 0.03x | 0.02x | 0.08x | 0.08x | 0.09x | 0.08x | 0.09x |
Debt / EBITDA | 0.09x | 0.03x | 0.13x | 0.41x | 0.17x | 0.86x | 0.97x | 0.30x | 0.19x | 0.18x |
Net Debt / EBITDA | -1.01x | -0.68x | -0.57x | -2.27x | -1.98x | -1.40x | -0.37x | -0.04x | -0.34x | -0.06x |
Interest Coverage | 19.25x | - | - | - | - | - | - | - | - | - |
Total Equity | 284.96M▲ 0% | 1.29B▲ 351.8% | 1.69B▲ 31.0% | 1.88B▲ 11.5% | 2.21B▲ 17.6% | 2.49B▲ 12.6% | 2.26B▼ 9.0% | 2.24B▼ 0.9% | 2.16B▼ 3.7% | 1.94B▲ 0% |
Equity Growth % | 219.04% | 351.8% | 30.95% | 11.46% | 17.64% | 12.57% | -9.02% | -0.87% | -3.69% | -21.96% |
Book Value per Share | 0.91 | 4.12 | 5.35 | 5.91 | 6.86 | 7.67 | 7.04 | 7.58 | 7.67 | 7.24 |
Total Shareholders' Equity | 284.96M | 1.29B | 1.69B | 1.88B | 2.21B | 2.49B | 2.26B | 2.24B | 2.16B | 1.94B |
Common Stock | 296K | 300K | 305K | 312K | 319K | 324K | 303K | 282K | 262K | 254K |
Retained Earnings | -1.83B | -880.36M | -559.35M | -447.57M | -216.51M | -34.23M | -173.35M | -98.65M | -76.83M | -215.79M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -347K | -701K | 3.07M | 4.48M | -758K | -14.52M | -3.75M | -1.35M | 3.48M | -415K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EXEL Cash Flow Statement
Exelixis, Inc. (EXEL) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Jan'25 | Jan'26 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 165.61M | 415.72M | 526.96M | 208.98M | 400.8M | 362.61M | 333.32M | 699.97M | 884.27M | 924.67M |
Operating CF Margin % | 36.6% | 48.69% | 54.45% | 21.16% | 27.93% | 22.51% | 18.21% | 32.28% | 38.11% | - |
Operating CF Growth % | -19.72% | 151.02% | 26.76% | -60.34% | 91.79% | -9.53% | -8.08% | 110% | 26.33% | 5.9% |
Net Income | 154.23M | 690.07M | 321.01M | 111.78M | 231.06M | 182.28M | 207.76M | 521.27M | 782.57M | 833.42M |
Depreciation & Amortization | 1.19M | 7.77M | 8.35M | 9.14M | 13.63M | 20.88M | 25.72M | 28.8M | 29.05M | 28.66M |
Stock-Based Compensation | 23.94M | 44.32M | 56.6M | 105.07M | 119.82M | 107.57M | 106.34M | 93.84M | 112.98M | 116.1M |
Deferred Taxes | 3.26M | -244.11M | 71M | 15.27M | 46.53M | -60.36M | -133.21M | -59.46M | 126.24M | 0 |
Other Non-Cash Items | -10.05M | -2.57M | 2.91M | 7.87M | 28.77M | 125.04M | 140.68M | 128.98M | 24.62M | 154.93M |
Working Capital Changes | -6.95M | -79.76M | 67.08M | -40.14M | -39.01M | -12.8M | -13.97M | -13.45M | -191.2M | -208.43M |
Change in Receivables | -40.84M | -85.47M | 43.72M | -42.47M | -122.32M | 66.85M | -22.62M | -27.95M | -21.4M | -47.31M |
Change in Inventory | -3.32M | -3.18M | -5.73M | -21.9M | -13.21M | -11.68M | -12.98M | 5.45M | 12.22M | 8.91M |
Change in Payables | 3.01M | 856K | 39.69M | 50.51M | 55.09M | 23.36M | 53.25M | -21.89M | -50.15M | -76.55M |
Cash from Investing | 35.8M | -297.85M | -587.25M | -131.22M | -42.88M | -524.41M | -26.95M | -116.78M | 350.44M | 249.61M |
Capital Expenditures | -21.14M | -33.3M | -12.83M | -30.34M | -54.23M | -27.71M | -40.47M | -28.43M | 0 | -2.64M |
CapEx % of Revenue | 4.67% | 3.9% | 1.33% | 3.07% | 3.78% | 1.72% | 2.21% | 1.31% | 1.72% | 0.11% |
Acquisitions | 164K | 308K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1M | 308K | 0 | 0 | -10M | -110.75M | -122.5M | -37.75M | -61.75M | -16.87M |
Cash from Financing | -169.93M | 9.69M | 12.55M | -25.13M | -14.8M | 586K | -546.05M | -628.81M | -969.59M | -1.13B |
Debt Issued (Net) | -185.79M | -13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -550.38M | -652.03M | -898.37M | -626.07M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -6.56M | -7.57M | 0 | 0 | 0 | 0 | -550.38M | -652.03M | -947.51M | -1.09B |
Other Financing | 15.86M | 9.7M | 12.55M | -25.13M | -14.8M | 586K | 4.33M | 23.23M | -71.22M | -505.81M |
Net Change in Cash | 31.48M▲ 0% | 127.56M▲ 305.2% | -47.74M▼ 137.4% | 52.63M▲ 210.3% | 343.12M▲ 551.9% | -161.21M▼ 147.0% | -239.68M▼ 48.7% | -45.62M▲ 81.0% | 265.11M▲ 681.1% | 256K▲ 0% |
Free Cash Flow | 144.47M▲ 0% | 382.42M▲ 164.7% | 514.12M▲ 34.4% | 178.64M▼ 65.3% | 336.58M▲ 88.4% | 224.16M▼ 33.4% | 170.35M▼ 24.0% | 633.79M▲ 272.0% | 844.34M▲ 33.2% | 918.45M▲ 0% |
FCF Margin % | 31.93% | 44.79% | 53.12% | 18.09% | 23.46% | 13.91% | 9.31% | 29.22% | 36.39% | 38.66% |
FCF Growth % | -29.39% | 164.71% | 34.44% | -65.25% | 88.42% | -33.4% | -24% | 272.04% | 33.22% | 18.95% |
FCF per Share | 0.46 | 1.22 | 1.63 | 0.56 | 1.04 | 0.69 | 0.53 | 2.14 | 3.00 | 3.44 |
FCF Conversion (FCF/Net Income) | 1.07x | 0.60x | 1.64x | 1.87x | 1.73x | 1.99x | 1.60x | 1.34x | 1.13x | 1.10x |
Interest Paid | 20.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 538K | 10.68M | 7.87M | 4.12M | 12.96M | 127.87M | 185.66M | 170.48M | 155.3M | 0 |
EXEL Key Ratios
Exelixis, Inc. (EXEL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 82.41% | 87.77% | 21.59% | 6.27% | 11.3% | 7.76% | 8.74% | 23.13% | 35.53% | 40.21% |
Return on Invested Capital (ROIC) | 102.38% | 59.63% | 22.55% | 5.36% | 13.34% | 7.97% | 5.87% | 20.57% | 32.15% | 36.3% |
Gross Margin | 96.67% | 96.91% | 96.58% | 96.33% | 96.32% | 96.41% | 96.04% | 96.49% | 96.39% | 71.57% |
Net Margin | 34.09% | 80.82% | 33.17% | 11.32% | 16.1% | 11.31% | 11.35% | 24.04% | 33.73% | 35.08% |
Debt / Equity | 0.05x | 0.01x | 0.03x | 0.03x | 0.02x | 0.08x | 0.08x | 0.09x | 0.08x | 0.09x |
Interest Coverage | 19.25x | - | - | - | - | - | - | - | - | - |
FCF Conversion | 1.07x | 0.60x | 1.64x | 1.87x | 1.73x | 1.99x | 1.60x | 1.34x | 1.13x | 1.10x |
Revenue Growth | 136.34% | 88.7% | 13.35% | 2.04% | 45.31% | 12.27% | 13.6% | 18.49% | 6.98% | 3.33% |
Related:EXEL Dividend History·EXEL Revenue History·EXEL Price History·EXEL P/E History·EXEL Financial Ratios·EXEL Institutional Holders
EXEL SEC Filings & Documents
Exelixis, Inc. (EXEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
EXEL Frequently Asked Questions
Exelixis, Inc. (EXEL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Exelixis, Inc. (EXEL) reported $2.38B in revenue for fiscal year 2025. This represents a 22524% increase from $10.5M in 1999.
Exelixis, Inc. (EXEL) grew revenue by 7.0% over the past year. This is steady growth.
Yes, Exelixis, Inc. (EXEL) is profitable, generating $833.4M in net income for fiscal year 2025 (33.7% net margin).
Dividend & Returns
Exelixis, Inc. (EXEL) has a return on equity (ROE) of 35.5%. This is excellent, indicating efficient use of shareholder capital.
Exelixis, Inc. (EXEL) generated $918.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.